[IN THE PIPELINE] Amazon Biotech

[Robert18]

Source: Amazon Biotech, Inc.

Amazon Biotech Inc. Retains Strategic Growth as Investor Relations Advisor

NEW YORK, July 7, 2004 (PRIMEZONE) -- Amazon Biotech Inc. (OTCBB:AMZB), a New York-based pharmaceutical company engaged in the development of novel all-natural drugs, announced it has retained Strategic Growth International, Inc. ("SGI"), a worldwide investor relations firm.

Amazon Biotech's goal is to be a world leader and contributor in the treatment of HIV naturally -- through the use of Immune-based therapies (IBT). In order to facilitate this vision, we wanted to enlist the resources of a major investor relations firm that is well known by growth company investors. Strategic Growth's expertise will help us to identify institutions that recognize the value of our unique AIDS drug -- AMZ 0026, from both scientific and investment perspectives.

Founded in 1989, SGI is headed by Richard Cooper and Stanley Altschuler, two long-time and highly respected Wall Street veterans, who have assembled an experienced team of investment/financial professionals. Since its inception in 1989, Strategic Growth has achieved an unparalleled level of excellence and success, particularly in the biotechnology and health services sectors.

Leading this account for SGI is Richard E. Cooper, Chairman and co-founder of Strategic Growth International, Inc. Prior to his co-founding SGI, Mr. Cooper was a Managing Director at Salomon Brothers for five of his 14 years at the firm.

About Amazon Biotech, Inc.

Amazon Biotech, Corp. is a newly established pharmaceutical company currently producing AMZ 0026 and a revolutionary, topical natural hair-growth product. The Company intends to initiate Phase I/II clinical studies of AMZ 0026 shortly, with an eventual goal of a joint venture with a major pharmaceutical company in Phase III trials. During 2004, Amazon Biotech plans to conduct a double blind study on its hair growth product. The Company also plans to market the hair growth product through a Fortune 1000 company. Additional information on Amazon Biotech may be found at www.amazonbiotech.com

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT: Investor RelationsRichard E. Cooper / Jennifer K. Zimmons, Ph.D. Strategic Growth International, Inc.jzimmons@sgi-ir.com212-838-1444

http://www.amazonbiotech.com/products.htm

[pizzacat]

Ben benieuwd, goed om te weten dat er nu een aantal verschillende invalshoeken voor het probleem worden gekozen en dat er veel onderzoek naar gedaan wordt.

Dus de lijst met expected products.

-Osteoscreen (schijnt beter te werken dan minox en fina)
-RUxxxx
-Dit nieuwe all natural product
-Gentherapie gebaseerde methoden
-Hair multiplication als HT techniek (zal nog wel ff duren)
-RK19 (ik verwacht er niet zoveel van trouwens)
-LED therapie (door de drukte heb ik nog niet zon Led matrix kunnen bouwen, hoop ik binnen enkele weken gereed te hebben, ik houd u allen op den hoogte )

Dus het blijft spannend in de business!